Vie Ventures

Deep expertise.Shared conviction.

Vie Ventures' Managing Directors come from the venture capital and biopharmaceutical industries with deep personal connections to autoimmune disease and philanthropy.

Managing Directors

Steven St. Peter, MD and Luke Evnin, PhD worked together at MPM Capital, where they invested in three successive venture capital funds. Each brings a successful track record of life sciences investing and organizational leadership, and both are excited to have reunited at Vie Ventures alongside Jeff Bluestone, PhD, a globally recognized leader in immunology and immune tolerance.

Together, Steven, Luke, and Jeff bring deep and complementary expertise in Immunology & Autoimmunity (I&A), including leadership across venture investing, academia, biotech company building, and patient-focused philanthropy. They are committed to leveraging these strengths and deep, personal networks with venture capital and public market investors to accelerate the development of innovative therapeutics.

Steven St. Peter, MD

Steven St. Peter, MD

Co-Founder & Managing Director

  • Multiple successful investments and exits.
  • Founder and CEO of Aratana Therapeutics through IPO and commercialization.
  • Leader of one of the largest dedicated venture philanthropy funds.
  1. 2004–2012

    Managing Director

    MPM Capital

  2. 2012–2019

    Founder, President & CEO

    Aratana Therapeutics

  3. 2019–2025

    Managing Director

    T1D Fund

  4. 2025–Present

    Co-founder and Managing Director

    Vie Ventures

Meet Steven: bio and video
Luke Evnin, PhD

Luke Evnin, PhD

Co-Founder & Managing Director

  • Created and built dozens of successful companies.
  • Co-recipient of the Global Oncology Visionary Award.
  • Three-plus decades of life-sciences venture investing.
  1. 1997–2023

    Co-Founder & Managing Director

    MPM Capital

  2. 2002–Present

    Chairman

    Scleroderma Research Foundation

  3. 2025–Present

    Co-founder and Managing Director

    Vie Ventures

Meet Luke: bio and video
Jeff Bluestone, PhD

Jeff Bluestone, PhD

Managing Director

  • International leader in immune tolerance and regulatory T cells.
  • Pioneer and thought leader for cells as medicines.
  • Four-plus decades of scientific and translational leadership, including UCSF and the Immune Tolerance Network.
  1. 2015–2019

    CEO & President

    Parker Institute for Cancer Immunotherapy

  2. 2019–2025

    Co-Founder & CEO

    Sonoma Biotherapeutics

  3. Present

    Co-Founder

    Monocacy Therapeutics

  4. Present

    Managing Director

    Vie Ventures

Meet Jeff: bio and video

Our team

Our team brings complementary experience in disease-community engagement, financial management, and investment operations.

LD

Lou DeGennaro, PhD

Senior Advisor

Lou is the former CEO of the Leukemia and Lymphoma Society, and has been an advisor to Vie Ventures since fall 2024. Given the scientific and biological links between immuno-oncology and autoimmune disease, Lou's involvement is particularly useful and relevant. Lou is primarily focused on implementing and managing Vie Ventures' strategic collaborator relationships.

SB

Shane Bates

Chief Financial Officer

Shane is a Founder and Partner at Bridge Alternatives, a leading alternative investment services platform. Supported by a team of professionals at Bridge Alternatives, Shane leads operations and serves as the CFO of Vie Ventures.

A team united by conviction.

We bring deep, complementary expertise across venture investing, academia, biotech company building, and patient-focused philanthropy.

Or email us directly at contact@vieventures.com.